Filing Details
- Accession Number:
- 0001562180-23-000950
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-03 16:59:20
- Reporting Period:
- 2023-01-31
- Accepted Time:
- 2023-02-03 16:59:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1395937 | Syndax Pharmaceuticals Inc | SNDX | Pharmaceutical Preparations (2834) | 320162505 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1594274 | Peter Ordentlich | C/O Syndax Pharmaceuticals, Inc. 35 Gatehouse Drive, Building D, Floor 3 Waltham MA 02451 | Chief Scientific Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-01-31 | 69 | $17.32 | 69 | No | 4 | J | Direct | |
| Common Stock | Disposition | 2023-02-01 | 69 | $28.43 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | J | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to buy) | Acquisiton | 2023-02-02 | 90,000 | $28.55 | 90,000 | $28.55 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 90,000 | 2033-02-02 | No | 4 | A | Direct |
Footnotes
- The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 69 shares by the Reporting Person on 01/31/2023 pursuant to the Issuer's Employee Stock Purchase Plan.
- 1/48th of the shares subject to the option shall vest monthly over a four-year period.
Billionaire Hedge Funds
